You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

INQOVI

Showing 1 - 25 of 25
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

MDS Trial run by the National Cancer Institute (NCI) (KPT-8602, Inqovi)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jun 30, 2023

Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma Trial run by the National Cancer Institute (NCI)

Not yet recruiting
  • Mesothelioma
  • +5 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 1, 2023

Acute Myeloid Leukemia Trial in Houston (ASTX727, ASTX029-01)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Houston, Texas
    MD Anderson Cancer Center
Oct 27, 2023

MDS Trial (Decitabine/Cedazuridine, Magrolimab)

Not yet recruiting
  • Myelodysplastic Syndromes
  • (no location specified)
Apr 18, 2023

MDS, Chronic Myelomonocytic Leukemia, Stem Cell Leukemia Trial in Boston (Inqovi)

Recruiting
  • Myelodysplastic Syndromes
  • +2 more
  • Inqovi
  • Boston, Massachusetts
    Massachusetts General Hospital
Sep 29, 2021

MDS Trial in Saint Louis (DEC-C, MyeloSeq-HD)

Recruiting
  • Myelodysplastic Syndromes
  • Saint Louis, Missouri
    Washington University School of Medicine
Jan 18, 2023

MDS, Leukemia, Myelomonocytic, Chronic Trial (decitabine, Spartalizumab, Sabatolimab)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Leukemia, Myelomonocytic, Chronic
  • (no location specified)
Aug 5, 2022

MDS, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia Trial in Sydney (Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET,

Recruiting
  • Myelodysplastic Syndromes
  • +2 more
  • Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET
  • Defactinib
  • Sydney, New South Wales, Australia
  • +3 more
Jan 12, 2023

Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma

Not yet recruiting
  • Anatomic Stage III Breast Cancer AJCC v8
  • +3 more
  • Biopsy
  • +4 more
  • (no location specified)
Jan 4, 2023

Castration-Resistant Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8 Trial in Buffalo

Recruiting
  • Castration-Resistant Prostate Carcinoma
  • +3 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Jul 27, 2022

Acute Myeloid Leukemia Trial in Houston (Decitabine and Cedazuridine, Enasidenib, Gilteritinib)

Recruiting
  • Acute Myeloid Leukemia
  • Decitabine and Cedazuridine
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 10, 2022

Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome Trial in Houston (Decitabine and Cedazuridine, Venetoclax)

Recruiting
  • Chronic Myelomonocytic Leukemia
  • Myelodysplastic Syndrome
  • Houston, Texas
    M D Anderson Cancer Center
Jul 18, 2022

Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts Trial (Biospecimen

Not yet recruiting
  • Chronic Myelomonocytic Leukemia
  • +3 more
  • Biospecimen Collection
  • +3 more
  • (no location specified)
Oct 27, 2022

Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Portland (Decitabine and

Not yet recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Decitabine and Cedazuridine
  • +2 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
May 25, 2022

Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

Recruiting
  • Chronic Phase Chronic Myelogenous Leukemia
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 11, 2022

Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Decitabine and

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Decitabine and Cedazuridine
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 29, 2022

Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Decitabine and

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Apr 1, 2022

Myelodysplastic Syndrome (MDS) Trial in United States (MBG453, Azacitidine, Decitabine)

Recruiting
  • Myelodysplastic Syndrome (MDS)
  • Chandler, Arizona
  • +22 more
Dec 5, 2022

Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia Trial in Houston (Decitabine and

Recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Decitabine and Cedazuridine
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Apr 19, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL, Recurrent Hodgkin Lymphoma Trial in New York (Decitabine and

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +5 more
  • Decitabine and Cedazuridine
  • Nivolumab
  • New York, New York
    NY011 Laura and Isaac Perlmutter Cancer Center at NYU Langone
Jul 8, 2022

Acute Myeloid Leukemia Trial in Nashville (Biopsy of Bone, Cytarabine, Daunorubicin)

Recruiting
  • Acute Myeloid Leukemia
  • Biospecimen Collection
  • +5 more
  • Buffalo, New York
  • +1 more
Jan 27, 2023

Acute Myeloid Leukemia Trial in Canada, Spain, United States (Decitabine and Cedazuridine (ASTX727), Venetoclax)

Recruiting
  • Acute Myeloid Leukemia
  • Los Angeles, California
  • +15 more
Jul 29, 2022

Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, MDS Trial in Canada, United States (ASTX727)

Enrolling by invitation
  • Acute Myeloid Leukemia
  • +2 more
  • Fountain Valley, California
  • +28 more
Nov 18, 2022

Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma, Unresectable Primary

Suspended
  • Locally Advanced Unresectable Primary Central Chondrosarcoma
  • +2 more
  • Phoenix, Arizona
  • +38 more
Feb 2, 2023

Malignant Peripheral Nerve Sheath Tumors (MPNST) Trial in United States (ASTX727)

Recruiting
  • Malignant Peripheral Nerve Sheath Tumors (MPNST)
  • Basking Ridge, New Jersey
  • +6 more
Aug 25, 2022